Trial Search Results
Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial
The objective of the PORTICO pivotal IDE trial is to evaluate the safety and effectiveness of the St Jude Medical (SJM) Portico Transcatheter Heart Valve and Delivery Systems (Portico) in the treatment of severe symptomatic aortic stenosis via transfemoral and alternative delivery methods in high risk and extreme risk patients.
Stanford is currently accepting patients for this trial.
Abbott Medical Devices
- Device: Portico transcatheter aortic valve
- Device: Commercially available transcatheter aortic valve
1. Subjects must have co-morbidities such that the surgeon and cardiologist
Co-Investigators concur that the predicted risk of operative mortality is ≥15% or a
minimum Society of Thoracic Surgeons (STS) score of 8%. A candidate who does not meet
the STS score criteria of ≥ 8% can be included in the study if a peer review by at
least two surgeons concludes and documents that the patient's predicted risk of
operative mortality is ≥15%. The surgeon's assessment of operative comorbidities not
captured by the STS score must be documented in the study case report form as well as
in the patient medical record.
2. Subject is 21 years of age or older at the time of consent.
3. Subject has senile degenerative aortic valve stenosis with echocardiographically
derived criteria: mean gradient >40 mmHg or jet velocity greater than 4.0 m/s or
Doppler Velocity Index <0.25 and an initial aortic valve area (AVA) of ≤ 1.0 cm2
(indexed effective orifice area (EOA) ≤ 0.6 cm2/m2). (Qualifying AVA baseline
measurement must be within 60 days prior to informed consent).
4. Subject has symptomatic aortic stenosis as demonstrated by New York Heart Association
(NYHA) Functional Classification of II, III, or IV.
5. The subject has been informed of the nature of the study, agrees to its provisions and
has provided written informed consent as approved by the Institutional Review Board
(IRB) of the respective clinical site.
6. The subject and the treating physician agree that the subject will return for all
required post-procedure follow-up visits.
7. Subject's aortic annulus is 19-27mm diameter as measured by computerized tomography
(CT) conducted within 12 months prior to informed consent. Note: if CT is
contraindicated and/or not possible to be obtained for certain subjects, a 3D echo and
non-contrast CT of chest and abdomen/pelvis may be accepted if approved by the subject
For a subject to be considered an Extreme Risk candidate they must meet # 2, 3, 4, 5,
6, 7 of the above criteria, and
8. The subject, after formal consults by a cardiologist and two cardiovascular surgeons
agree that medical factors preclude operation, based on a conclusion that the
probability of death or serious, irreversible morbidity exceeds the probability of
meaningful improvement. Specifically, the probability of death or serious,
irreversible morbidity should exceed 50%. The surgeons' consult notes shall specify
the medical or anatomic factors leading to that conclusion and include a printout of
the calculation of the STS score to additionally identify the risks in these patients.
1. Evidence of an acute myocardial infarction (defined as: ST Segment Elevation as
evidenced on 12 Lead ECG) within 30 days prior to index procedure.
2. Aortic valve is a congenital unicuspid or congenital bicuspid valve or is
non-calcified as verified by echocardiography.
3. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant
aortic regurgitation 3-4+).
4. Any percutaneous coronary or peripheral interventional procedure performed within 30
days prior to index procedure.
5. Pre-existing prosthetic heart valve or other implant in any valve position, prosthetic
ring, severe circumferential mitral annular calcification (MAC) which is continuous
with calcium in the left ventricular outflow tract (LVOT), severe (greater than 3+)
mitral insufficiency, or severe mitral stenosis with pulmonary compromise. Subjects
with pre-existing surgical bioprosthetic aortic heart valve should be considered for
the Valve-in-Valve registry.
6. Blood dyscrasias as defined: leukopenia (WBC<3000 mm3), acute anemia (Hb < 9 g/dL),
thrombocytopenia (platelet count <50,000 cells/mm³).
7. History of bleeding diathesis or coagulopathy.
8. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or
mechanical hemodynamic support.
9. Untreated clinically significant coronary artery disease requiring revascularization.
10. Hemodynamic instability requiring inotropic support or mechanical heart assistance.
11. Need for emergency surgery for any reason.
12. Hypertrophic cardiomyopathy with or without obstruction (HOCM).
13. Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) <20% as
measured by resting echocardiogram.
14. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.
15. Active peptic ulcer or upper gastrointestinal (GI) bleeding within 3 months prior to
16. A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine
(Ticlid), or clopidogrel (Plavix), or sensitivity to contrast media which cannot be
17. Recent (within 6 months prior to index procedure date) cerebrovascular accident (CVA)
or a transient ischemic attack (TIA).
18. Renal insufficiency (creatinine > 3.0 mg/dL) and/or end stage renal disease requiring
19. Life expectancy < 12 months from the time of informed consent due to non-cardiac
20. Significant aortic disease, including abdominal aortic or thoracic aneurysm defined as
maximal luminal diameter 5cm or greater; marked tortuosity (hyperacute bend), aortic
arch atheroma (especially if thick [> 5 mm], protruding or ulcerated) or narrowing
(especially with calcification and surface irregularities) of the abdominal or
thoracic aorta, severe "unfolding" and tortuosity of the thoracic aorta (applicable
for transfemoral patients only).
21. Native aortic annulus size < 19 mm or > 27 mm per the baseline diagnostic imaging.
22. Aortic root angulation > 70° (applicable for transfemoral patients only).
23. Currently participating in an investigational drug or device study.
24. Active bacterial endocarditis within 6 months prior to the index procedure.
25. Bulky calcified aortic valve leaflets in close proximity to coronary ostia.
26. Non-calcified aortic annulus
27. Iliofemoral vessel characteristics that would preclude safe placement of the
introducer sheath such as severe obstructive calcification, or severe tortuosity
(applicable for transfemoral patients only).
Additional Exclusion Criteria (Transcatheter Access Related)
For selection of an appropriate alternative access delivery method, subjects were screened
using the following access specific exclusion criteria:
Transaortic (TAo) Subject Cohort Specific Exclusion Criteria
1. Subject has pre-existing patent RIMA graft that would preclude access.
2. Subject has a hostile chest or other condition that complicates transaortic access.
3. Subject has a porcelain aorta, defined as an extensive circumferential calcification
of the ascending aorta that would complicate TAo access.
Additional exclusion criteria for transaortic access using the FlexNav™ Delivery System:
1. Subject has a distance between the annular plane and the aortic access site <7 cm
2. Subject has a distance between the annular plane and the separate introducer sheath
distal tip <6 cm (2.4")
Subclavian/Axillary Subject Cohort Specific Exclusion Criteria
1. Subject's access vessel (subclavian/axillary) diameter will not allow for introduction
of the applicable 18 Fr or 19 Fr delivery system.
2. Subject's subclavian/axillary arteries have severe calcification and/or tortuosity.
3. Subject's aortic root angulation is:
- Left Subclavian/Left Axillary: >70◦
- Right Subclavian/Right Axillary: >30◦
4. Subject has a history of patent LIMA/RIMA graft that would preclude access
Additional exclusion criteria for subclavian/axillary access using the FlexNav™ Delivery
1. Subject's access vessel (subclavian/axillary) has a distance between the annular plane
and the integrated sheath distal tip <17 cm (6.7")
2. Subject's access vessel requires the delivery system to be advanced through a separate
Ages Eligible for Study
21 Years - N/A
Genders Eligible for Study